Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Details) - Schedule of segment reporting information, by segment

v2.4.0.8
Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Revenues:    
Clinical laboratory services $ 15,822 $ 14,860
Product revenues 8,002 7,663
Royalty and license fee income 1,000 1,611
Total revenues 24,824 24,134
Operating expenses:    
Cost of clinical laboratory services 10,130 9,709
Cost of product revenues 3,695 3,846
Research and development 791 817
Selling, general and administrative 10,285 10,529
Provision for uncollectible accounts receivable 541 872
Legal fee expense 2,466 1,381
Operating income (loss) (3,084) (3,020)
Other income (expense)    
Other 19 61
Foreign exchange (472) 297
Share-based compensation included in above:    
Share-based compensation 98 103
Cost of Clinical Laboratory Services [Member] | Clinical Labs [Member]
    
Share-based compensation included in above:    
Share-based compensation 1 2
Cost of Clinical Laboratory Services [Member] | Consolidated [Member]
    
Share-based compensation included in above:    
Share-based compensation 1 2
Cost of Clinical Laboratory Services [Member]
    
Share-based compensation included in above:    
Share-based compensation 1 2
Research and Development Expense [Member] | Life Sciences [Member]
    
Share-based compensation included in above:    
Share-based compensation 1 1
Research and Development Expense [Member] | Consolidated [Member]
    
Share-based compensation included in above:    
Share-based compensation 1 1
Research and Development Expense [Member]
    
Share-based compensation included in above:    
Share-based compensation 1 1
Selling, General and Administrative Expenses [Member] | Clinical Labs [Member]
    
Share-based compensation included in above:    
Share-based compensation 9 10
Selling, General and Administrative Expenses [Member] | Life Sciences [Member]
    
Share-based compensation included in above:    
Share-based compensation   4
Selling, General and Administrative Expenses [Member] | Other Segments [Member]
    
Share-based compensation included in above:    
Share-based compensation 87 86
Selling, General and Administrative Expenses [Member] | Consolidated [Member]
    
Share-based compensation included in above:    
Share-based compensation 96 100
Selling, General and Administrative Expenses [Member]
    
Share-based compensation included in above:    
Share-based compensation 96 100
Total [Member] | Clinical Labs [Member]
    
Share-based compensation included in above:    
Share-based compensation 10 12
Total [Member] | Life Sciences [Member]
    
Share-based compensation included in above:    
Share-based compensation 1 5
Total [Member] | Other Segments [Member]
    
Share-based compensation included in above:    
Share-based compensation 87 86
Total [Member] | Consolidated [Member]
    
Share-based compensation included in above:    
Share-based compensation 98 103
Clinical Labs [Member]
    
Revenues:    
Clinical laboratory services 15,822 14,860
Total revenues 15,822 14,860
Operating expenses:    
Cost of clinical laboratory services 10,130 9,709
Research and development   11
Selling, general and administrative 5,066 5,050
Provision for uncollectible accounts receivable 530 844
Legal fee expense 91 148
Total operating expenses 15,817 15,762
Operating income (loss) 5 (902)
Other income (expense)    
Interest (27) (11)
Other 2 18
Income (loss) before income taxes (20) (895)
Depreciation and amortization included above 357 355
Share-based compensation included in above:    
Capital expenditures 254 259
Life Sciences [Member]
    
Revenues:    
Product revenues 8,002 7,663
Royalty and license fee income 1,000 1,611
Total revenues 9,002 9,274
Operating expenses:    
Cost of product revenues 3,695 3,846
Research and development 548 526
Selling, general and administrative 3,150 3,495
Provision for uncollectible accounts receivable 11 28
Legal fee expense 1 22
Total operating expenses 7,405 7,917
Operating income (loss) 1,597 1,357
Other income (expense)    
Interest 2 5
Other (8) 27
Foreign exchange (472) 297
Income (loss) before income taxes 1,119 1,686
Depreciation and amortization included above 560 641
Share-based compensation included in above:    
Capital expenditures 10 75
Therapeutics [Member]
    
Operating expenses:    
Research and development 243 280
Total operating expenses 243 280
Operating income (loss) (243) (280)
Other income (expense)    
Income (loss) before income taxes (243) (280)
Depreciation and amortization included above 1 4
Other Segments [Member]
    
Operating expenses:    
Selling, general and administrative 2,069 1,984
Legal fee expense 2,374 1,211
Total operating expenses 4,443 3,195
Operating income (loss) (4,443) (3,195)
Other income (expense)    
Interest (44) (56)
Other 25 16
Income (loss) before income taxes (4,462) (3,235)
Depreciation and amortization included above 20 25
Consolidated [Member]
    
Revenues:    
Clinical laboratory services 15,822 14,860
Product revenues 8,002 7,663
Royalty and license fee income 1,000 1,611
Total revenues 24,824 24,134
Operating expenses:    
Cost of clinical laboratory services 10,130 9,709
Cost of product revenues 3,695 3,846
Research and development 791 817
Selling, general and administrative 10,285 10,529
Provision for uncollectible accounts receivable 541 872
Legal fee expense 2,466 1,381
Total operating expenses 27,908 27,154
Operating income (loss) (3,084) (3,020)
Other income (expense)    
Interest (69) (62)
Other 19 61
Foreign exchange (472) 297
Income (loss) before income taxes (3,606) (2,724)
Depreciation and amortization included above 938 1,025
Share-based compensation included in above:    
Capital expenditures $ 264 $ 334